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Abstract Giant pituitary adenomas (GPAs), defined
as ≥40 mm in one extension, present a challenging subgroup
of pituitary adenomas in terms of radical tumor removal and
complication rates. The potential impact of intraoperative
magnetic resonance imaging (iMRI) is investigated in a
consecutive series and the results compared to the literature.
From November 2004 until February 2005, six (five male)
patients were operated for GPAs via an iMRI-guided trans-
sphenoidal approach in the PoleStar™ N20. Clinical,
endocrinological, and neuroradiological outcomes (at
3 months and yearly postoperative over 4 years) were
assessed. Mean age was 46 years (range, 34–60). All patients
presented with preoperative visual field defects, five with
pituitary failure. Five adenomas were clinically nonfunction-
ing, one was producing GH and TSH. Preoperative imaging
showed invasion of the cavernous sinus in all and extension
to the interventricular foramen in two patients (one with
occlusive hydrocephalus). Resection was total in four and
subtotal (small cavernous sinus remnants) in two patients,
leading to transsphenoidal reoperation in one patient. Visual
acuity and fields improved in all six patients. The patient
with occlusive hydrocephalus developed a postoperative
cerebrospinal fluid leak (subsequently revised), two
patients developed temporary, one permanent central
diabetes insipidus, and one of them transient hyponatre-
mia. Compared to the preoperative situation, endocrine
status in the long-term follow-up (mean, 25 months)
remained unchanged in four and worsened in two. Two
patients were considered not to require hormone replace-
ment therapy. IMRI supports transsphenoidal resections of
GPAs because residual adenoma and related risk struc-
tures are easily detected and localized intraoperatively,
extending the restricted visual access of the microscope
beyond mere surface anatomy to a three-dimensional
view. More radical removal of adenomas in a single
surgical session combined with low complication rates are
accomplished. This may add to a favorable clinical and
endocrinological outcome in GPAs.
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Introduction
Giant pituitary adenomas (GPAs), which comprise a
subgroup of pituitary adenomas (PAs), are inconsistently
defined when it comes to size. Hardy's classification groups
PAs into four types, according to qualitative extensions [11,
14]. Other authors define GPAs as tumors ≥30 mm in
diameter [1, 8], as ≥40 mm in diameter [9, 10, 19], or as
tumors extending more than 40 mm from the midpoint of
the jugum sphenoidale or to within 6 mm of the
interventricular foramen [7, 12, 18]. Patients with GPAs
compared to patients with non-GPAs [8] more frequently
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present clinically with visual symptoms and headaches than
hormonal disturbances [1, 8, 9, 12, 14]. Most GPAs are
non-secreting, followed by growth hormone (GH) secretion
and prolactinomas [1, 8, 10, 12, 14]. Radiologically, these
tumors show more aggressive behavior with cavernous
sinus (CS), skull base, and paranasal sinus invasion.
Invasion or infiltration is not confined to a selected
adenoma size or diameter and varies according to literature
from 9% to 40%, but is more prevalent with larger tumors
[8, 16]. Additionally, GPAs can cause occlusive hydro-
cephalus by impairment of cerebrospinal fluid (CSF)
drainage [12].
Gross tumor resection, thus, presents a challenge to the
pituitary surgeon. Numerous strategies (transsphenoidal,
transcranial, radiotherapy, or a combination of these) have
been proposed [1, 14, 15], including insertion of a lumbar
subarachnoid catheter for saline infusion to deliver the
suprasellar tumor into the operative field by increasing
intracranial pressure [20]. Especially CS infiltration often
makes total resection demanding or impossible. Between
27.9% and 40% of tumors are excised totally according to
several reports [1, 8, 9], and surgery can improve the
primary symptom of the patient, diminished vision, in 65%
to 90% [1, 9].
The most frequent postoperative complications include
transient diabetes insipidus (DI) in 3.7% to 18.8% and CSF
leak with meningitis in 7.4% to 14.6% [8, 9]. In one study,
these complications were not significantly more frequent
than in non-giant PAs [8]. Permanent DI or panhypopitui-
tarism, third nerve palsy, and hemiparesis have been
reported, as well as death from massive bleeding in 2.2%
to 4.2% [8, 9].
Intraoperative magnetic resonance imaging (iMRI) has
been used in the operating room for over a decade. As far
as PAs are concerned, this imaging technique has led to a
more radical one-stage resection of these tumors and to a
decrease of perioperative morbidity and mortality [3, 5, 6,
13, 17], especially in macroadenomas with suprasellar
extension [4].
We report our experience with the use of the iMRI
in transsphenoidal surgery for GPAs, investigating the
impact of this imaging modality on the amount of
resection and complication rates, including long-term
clinical, ophthalmological, endocrinological, and neuro-
radiological follow-up.
Patients and methods
Patients with pituitary tumors ≥40 mm in one extension,
who were operated in the PoleStar™ N20 (0.15 Tesla,
Medtronic Navigation, Louisville, CO, USA) at the
Department of Neurosurgery of the University Hospital of
Zurich, Switzerland, between November 2004 and February
2005, were included in the study. This sample represents a
cluster of such patients during that time.
Preoperative assessment
Preoperative computed tomography (CT) and MRI scans of
the sellar region were performed to determine bony
structures as well as tumor configuration and localization
of the normal gland and pituitary stalk. All patients had an
endocrinological investigation for pituitary function as well
as ophthalmological exams.
In all patients, an iMRI-guided endonaso-transsphenoidal
approach was used. All operations were performed by the
senior author (RLB).
Surgical technique
The patient is placed in a supine position with the head
slightly reclined and fixed in an MRI-compatible head
holder. The radio frequency coil is attached around the
patient's head. To optimize imaging field and quality, the
center of the two adjustable magnets must be brought at a
level close to the center of the adenoma. In most patients, a
bandage is applied over the shoulders with careful traction
in a cranio-caudal direction to reach the most basal
structures (sphenoid sinus and clivus). The magnet's
position is tested by a 24-sec scan with 8 mm-slice
thickness and T2-like specifications (e-steady sequence).
The three-dimensional reconstruction allows immediate
corrections of the magnet's position if necessary. Then a
7-min 4 mm-slice gadolinium-enhanced T1-weighted scan,
which serves as baseline for neuronavigation, is performed.
A self-retaining endonasal speculum is inserted typically in
the contralateral nostril or in the nostril that corresponds to
the more spacious intrasphenoidal sinus, and its anterior
wall is displayed under the operating microscope. The nasal
mucosa is incised on the sphenoid crest with a disk knife in
an inverted T-shaped fashion, and the anterior wall of the
sphenoid sinus is removed with punches or a chisel,
depending on the thickness of the bone. The intrasphenoi-
dal mucosa and septum are removed with rongeur forceps
until the anterior wall of the sella turcica to its lateral
borders is displayed. This wall is then opened by a chisel,
and the dura is incised in an x-shaped fashion with a
bayonet-handled scalpel. Using tumor grasping forceps, a
suctioning device, and curettes of different sizes and
shapes, the tumor is debulked in a stepwise fashion.
Progress is verified by serial 3.5-min 4 mm-slice
gadolinium-enhanced T1-weighted scans. Before a scan, a
bone wax ball covered by a piece of a rubber glove is
inserted in the region of the sella. This ball, which packs the
region acting as a hemostatic by local compression, is
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visualized as an easily detectable signal-void on MRI scans
and facilitates the interpretation of the iMRI images. Blood
appears homogeneously hyperintense, whereas residual
adenoma has lower and more heterogeneous signal inten-
sity. After tumor removal, the sella turcica and sphenoid
sinus are packed with abdominal fat, covered with
preserved bone fragments, and sealed by tissue adhesive if
necessary (DuraSeal™, Confluent Surgical, Waltham, MA,
USA). No nasal packing is used routinely.
Postoperative follow-up
On the first postoperative day, a CT scan of the sellar region
was performed routinely for detection of postoperative
complications. In the days following the operation, electro-
lytes and fluid balance were monitored twice a day
(including daily weight) to detect DI or syndrome of
inappropriate antidiuretic hormone (SIADH) secretion. The
patients were asked to report any post-nasal drip (suggestive
of CSF leak). Postoperative neuro-ophthalmologic exams
were performed before the patients left the hospital.
Endocrinological follow-ups usually started at 1 month
after discharge. Clinical, endocrinological, and neuroradio-
logical outcomes were assessed 3 months postoperative and
continued in yearly intervals. Resection was assessed as
complete if imaging and endocrinological studies were
inconspicuous in this regard, i.e., no residual tumor visible
on MRI scans and, in active adenomas, no pituitary
hormone hypersecretion detectable.
Results
In the 4-month period, six patients (five men and one
woman) were included in the study. Age ranged from 34 to
60 years (mean, 46 years).
Preoperative findings
Visual disturbances were the leading symptom (100%) of
the patients with GPAs. Fatigue was a complaint in two
patients. Two male patients complained of sexual dysfunc-
tion. One patient presented with acromegaly. In one patient
with sudden onset of extreme headaches and presumed
subarachnoid hemorrhage, CT scan revealed pituitary
hemorrhage in a sellar tumor. One patient showed memory
deficits, urinary incontinence, and gait ataxia as primary
symptoms, which led to cerebral imaging and identification
of a large sellar mass with obstructive hydrocephalus
(Table 1, Fig. 1).
Examination on admittance showed visual field defects in
all patients: two had bitemporal hemianopia, three unilateral
hemianopia, and one had bitemporal quadrantanopia. Preop-
erative endocrinological testing revealed a normal hormonal
status in one patient and multiple hormonal insufficiencies in
five patients (83%): all of them had gonadotropin (GT)
deficiency (hypogonadism, with low GTs in the postmeno-
pausal female and low testosterone in the four male patients),
three had thyroid stimulating hormone (TSH) deficiency
(central hypothyroidism, low fT4), and four adrenocorticotro-
pin hormone (ACTH) deficiency (secondary adrenal failure,
low cortisol); in one patient with insufficiency of the pituitary-
adrenal axis but without central hypothyroidism and GH
deficiency, a combined hyperthyroidism and excess of GH
were found. The remaining five adenomas were clinically
nonfunctioning adenomas (NFAs).
Preoperative imaging studies revealed invasion of the
cavernous sinus in all and extension to the interventricular
foramen in two patients, resulting in the aforementioned
occlusive hydrocephalus in one patient.
Intraoperative findings
During resection of the adenoma, between two and six MR
scans were performed; typically 3.5–7-min 4 mm-slice
thickness gadolinium-enhanced T1-weighted scans. This
led to a summarized scanning time of approximately 14 to
28 min. In all but one patient, intraoperative scans revealed
residual tumor. Surgery was continued until no residual
adenoma was visible on the MR scans (Fig. 2). Intra-
operative debulking of the intrasellar part of the adenoma
additionally revealed the pituitary stalk indicating the
localization of compressed gland (pituitary stalk sign).
Total surgery time, including intraoperative imaging,
ranged between 2 and 4 h (mean 2.5 h).
Postoperative findings
All patients underwent iMRI-guided endonaso-transsphenoidal
tumor extirpation. The immunohistochemical profiles of the
NFAs were: luteinizing hormone (LH) and human chorionic
gonadotropin (hCG) in three each, and ACTH in one. Tumor
cells in one patient did not stain. All patients reported markedly
improved vision immediately following surgery. The patient
with preoperative hydrocephalus developed rhinoliquorrhea
from CSF fistula and required revision and a ventriculo-
peritoneal shunt. Apart from that, there were no surgical
complications. Postoperatively, two patients temporarily re-
quired desmopressin for central DI (an additional one
permanently), one of them developed transient SIADH
thereafter, which was treated with fluid restriction (Table 2,
Fig. 3).
Compared to the preoperative hormonal status, at
1 month postoperative, one patient improved (from anterior
pituitary insufficiency to only gonadotropin deficiency),
one patient remained unchanged (anterior pituitary
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insufficiency), and four patients turned out worse
(additional ACTH and TSH deficiency resulting in
anterior pituitary insufficiency in one; additional gonad-
otropin deficiency in one; panhypopituitarism with newly
developed ADH deficiency from anterior pituitary insuf-
ficiency in one; anterior pituitary insufficiency from
normal hormonal status in one). As all patients at least
had partial pituitary failure, all received hormone
replacement accordingly.
Clinical follow-up at 3 months postoperative showed
improvement of the preoperative symptoms (with hormone
replacement if necessary) as well normalization of the
visual fields in all patients. Neuroradiological follow-up at
3 months postoperative showed total resection in four and
subtotal resection in two patients with remaining tumor in
the cavernous sinus (Fig. 3). Due to persistent elevation of
insulin-like growth factor 1 (IGF-1)/GH, the patient with
acromegaly was reoperated 5 months later.
Endocrinological follow-ups between 18 and 32 months
postoperative showed further improvement in two patients
(normal status in one; gonadotropin deficiency in a 60-year-
old female) so that these were independent of hormonal
Table 1 Patient characteristics, preoperative symptoms and signs, and adenoma features
Patient
number
Sex Age at
diagnosis
Adenoma size
and type
Additional
neuroradiological
findings
Preoperative symptoms Preoperative signs Preoperative
hormonal status
1 F 60 50*45*34 mm
Inactive
Occlusive
hydrocephalus
Visual disturbance fatigue,
gait disturbance, urinary
incontinence, memory
deficits
Left hemianopia,
ataxia
GT deficiency
2 M 39 46*44*31 mm
Active (GH,
TSH)
None Visual disturbance,
sweating, tremor
Bitemporal
hemianopia,
acromegaly,
intermittent
cardiac
arrhythmias
GH, TSH
hypersecretion;
ACTH, GT
deficiency
3 M 36 50*50*50 mm
Inactive
None Visual disturbance
(transient diplopia),
sexual dysfunction
Bitemporal
hemianopia
ACTH, GT, TSH
deficiency
4 M 57 45*22*23 mm
Inactive
None Visual disturbance, fatigue,
sexual dysfunction
Left hemianopia ACTH, GT, TSH
deficiency
5 M 51 56*36*39 mm
Inactive
None Visual disturbance Left hemianopia Normal
6 M 34 44*38*27 mm
Inactive
Pituitary
hemorrhage
Visual disturbance
(diplopia), headache,
nausea, vomiting
Bitemporal upper
quadrantanopia
ACTH, GT, TSH
deficiency
M male, F female, ACTH adrenocorticotropic hormone, GH growth hormone, GT gonadotropin, MRI magnetic resonance imaging, TSH thyroid
stimulating hormone
Fig. 1 Preoperative neuroradiological imaging studies (coronal
section above, sagittal section below; each pair represents one patient,
patient 1 on the left, patient 6 on the right; all are T1-weighted
gadolinium-enhanced MRI scans, except in patient 5, sagittal section
is a CT scan with contrast media)
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replacement therapy in the longer run. Two of the NFA
patients (anterior pituitary insufficiency and panhypopi-
tuitarism, respectively) and the patient with GH/TSH
secreting adenoma remained unchanged. One patient's
endocrinological status worsened to an anterior pituitary
insufficiency. Therefore, compared to the preoperative
endocrinological situation, endocrine status in the long-
term follow-up remained unchanged in four and worsened
in two patients.
Additional neuroradiological follow-ups were performed
in five patients between 15 and 46 months postoperative.
These showed stable tumor in two with postoperative
minimal residual adenoma in the cavernous sinus (ques-
tionable in one with normal endocrine status, possibly scar
formation) and no recurrent tumor in the other patients
without residual adenomas. Due to persistent elevation of
IGF-1 (low GH) and residual adenoma in the cavernous
sinus, the acromegalic patient was evaluated for stereotactic
radiosurgery.
Discussion
Giant pituitary adenomas are not unanimously defined in
the literature concerning size (varying between ≥30 and
>40 mm) [1, 7–12, 14, 18, 19]. In this study, PAs ≥40 mm
in one extension were considered GPAs. Although it is
questionable whether the largest diameter itself represents
the grade of surgical difficulty, this definition seems
practicable and is accepted in the literature. In our
Fig. 2 Intraoperative consecu-
tive T1-weighted gadolinium-
enhanced MRI scans (coronal
section on the left, sagittal
reconstructions on the right)
illustrating the gradual removal
of the adenoma in a representa-
tive patient (patient number 4)
Neurosurg Rev (2010) 33:83–90 87
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experience, invasion of the cavernous sinus and the middle
cranial fossa present additional criteria that make radical
resection demanding. Especially with CS involvement, in
≥60% of cases only subtotal resection is accomplished [1,
8, 9]. Attempts to total extirpation result in high complica-
tion rates [8, 9]; therefore numerous strategies have been
proposed to overcome the dilemma between radicality and
safety [1, 14, 15, 20].
In 2004, Basso remarked that surgical treatment of
nonfunctioning GPAs presented poor results because of
the practical impossibility of radical tumor resection with
consequent high recurrence rates [2].
Supplementary guidance by iMRI can improve tumor
resection by presenting to the surgeon a three-dimensional
visualization of the tumor and its residuals not directly
accessible to the operating microscope or the endoscope,
which both display mere surface anatomy. Especially in
cases where residual adenoma is obscured by structures
such as arachnoid pouches, with CS invasion, or in
situations with pronounced hemorrhage, pathologic tissue
is likely to be left behind, and iMRI is offering added value.
With the support of fully integrated neuronavigation, tumor
is localized and removed. In addition, the pituitary gland,
which may often not be distinguished on diagnostic MRIs
and in the operative field due to blood, can be identified on
iMRI scans by following the direction of the stalk, which
becomes visible in most cases, even after just partial
debulking of the adenoma (pituitary stalk sign). We present
a small sample of six patients with GPAs, which all were
operated in a standardized endonaso-transsphenoidal way
by the senior author (RLB) in the Polestar™ N20 between
November 2004 and February 2005. The patients' charac-
teristics as well as preoperative clinical and endocrinolog-
ical symptoms are comparable with those patients presented
in other GPA series (Table 1) [1, 8, 9]. MRI scans revealed
invasion of the cavernous sinus in all patients (Fig. 1). All
patients had clinical improvement of preoperative symptoms
and normalization of visual field deficits. Apart from one
patient with postoperative CSF fistula (preoperative occlu-
sive hydrocephalus), which required revision, there were no
surgical complications, although a radical in four or almost
radical resection in two patients was accomplished.
Compared to the preoperative situation (Table 2),
endocrine status in the long-term follow-up (mean,
25 months) remained unchanged in four and worsened in
two. Two patients gained independence of hormone
replacement.
Long-term neuroradiological follow-up with serial MRI
scans (mean, 26 months) showed stable tumor in two
patients with postoperative CS rest and no residual or
recurrent tumor in the others (Fig. 3), although in one
patient with normal hormonal status, the CS enhancement
could be related to scar formation (Table 2, Fig. 3).
Comparison with other series is difficult as only surgical
outcome but no endocrinological complications or postop-
erative states (except for permanent DI) have been reported
[1, 8, 9].
Nonetheless, we can report a much higher total resection
rate of 66% (between 27.9% and 40% according to
literature), accompanied by at least as favorable endocrino-
logical outcome and symptom control as with conventional
pituitary surgery [1, 8, 9].
Conclusions
We believe these favorable outcomes are supported by the
use of intraoperative imaging, which serves as an intra-
operative quality control to resection and to preservation of
surrounding structures beyond that of the operating micro-
scope or endoscope. This intraoperative information trans-
lates into more radical resections that may lead to fewer
severe complications, fewer additional procedures (such as
transcranial complementary operations, hormonal replace-
Fig. 3 Postoperative neuroradiological follow-up with MRI scans (T2-weighted coronal section above, T1-weighted gadolinium-enhanced
section below; each pair represents one patient, patient 1 on the left, patient 6 on the right)
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ment therapy, radiotherapy), and to reduction of overall
costs of therapy of this difficult group of patients.
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Comments
Christopher Nimsky, Marburg, Germany
One of the major, widely accepted indications for intraoperative
magnetic resonance imaging is the so-called “resection control” in
surgery of pituitary adenomas. Intraoperative imaging acts as an
immediate intraoperative quality control, unexpected postoperative
findings are nearly excluded. Intraoperative imaging allows not only
to increase the extent of a resection, but also to increase the percentage
of complete removals.
The authors analyzed a special subset of pituitary adenomas
undergoing transsphenoidal surgery, tumors with a diameter larger
than 40 mm and could confirm the benefit of intraoperative imaging in
these complicated cases. The suprasellar extent of resection in
transsphenoidal surgery could be reliably assessed applying intra-
operative low-field magnetic resonance imaging. However, the
visualization of tiny intra- and parasellar structures will still be the
domain of intraoperative high-field magnetic resonance imaging.
Moshe Hadani, Ramat Gan, Israel
Intra operative imaging becomes an integral part of image guided
neurosurgery. The surgical approach to giant pituitary adenomas is a
challenge. This paper describes the application of intraoperative MRI
in the management of such tumors.
The number of patients is small, so statistical significant
conclusions are not available, however, there is a trend towards more
total and safer removal with the control by iMRI. It was previously
shown in larger series that intraopertive imaging increased the rate of
resection of pituitary macroadenomas of various dimensions. Trans-
sphenoidal resection of pituitary adenoma is one of the surgical
approaches which benefit a great deal from intraoperative imaging.
Hans Landolt, Aarau, Switzerland
The authors present a small series of six patients with giant
pituitary adenomas over 4 cm in size operated on 2004–2005 through
transsphenoidal microsurgical access using an intraoperative low
magnet field mri "polestar". All patients presented with visual deficits,
and in four cases, with partial pituitary insufficiencies.
One case was acromegalic. In all cases, the tumor extended in the
cavernous sinus. In two cases, a monro blockade was visible.
The surgical procedure described was the classical transsphenoidal
microsurgical approach first standardized by J.Hardy, additionally
guided by intraoperative navigation.
As innovation, the authors used intraoperative MRI imaging (iMRI)
allowing adjusting navigation and surgical procedure to the actualised
image information as already presented by them in abstracts since 1998.
The results are recovery of visual deficits in all cases and even
endocrinologically stable function in four cases and worsening only in
two cases after long-term follow-up, in spite of total removal of tumor
in four cases and silent remaining in one. One case remained with
diabetes insipidus. The acromegalic case was reoperated once more.
One case showed CSF leak.
In contrast to the literature about giant pituitary adenomas operated
without iMRI, this small series show excellent results. Beside the surgical
competence of the senior author, his use of actualized intraoperative
imaging helped decisively to attack tumor remnants specifically accord-
ing to the new images. Any pituitary surgeon will be surprised to see
nonsuspected tumor remnants using an iMRI. To visualize and to be able
to remove it during the same procedure are undiscutable advantages
especially in giant sellar tumors. Also, for smaller tumors iMRI helps to
raise learning curves dramatically, allowing an immediate feedback of the
aims achieved after each surgical step. The time needed for iMRI is
irrelevant compared to the advantages offered, as we also experienced in
Aarau since 2006. For transsphenoidal surgeons, an iMRI will become
soon the golden standard as soon as larger series will be published.
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